1. Aronson, JK . Medication errors: what they are, how they happen, and how to avoid them. QJM. 2009;102(8):513–521. doi:10.1093/qjmed/hcp052
Google Scholar | Crossref | Medline2. Henriksen, JN, Nielsen, LP, Hellebek, A, Poulsen, BK. Medication errors involving anticoagulants: data from the Danish patient safety database. Pharmacol Res Perspect. 2017;5(3):1–8. doi:10.1002/prp2.307
Google Scholar | Crossref3. ISMP . ISMP list of High-Alert Medications in Acute Care Settings. Published 2018. Accessed May 19, 2021. https://www.ismp.org/sites/default/files/attachments/2018-10/highAlert2018new-Oct2018-v1.pdf
Google Scholar4. Howard, RL, Avery, AJ, Slavenburg, S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136–147.
Google Scholar | Crossref | Medline | ISI5. Kongkaew, C, Hann, M, Mandal, J, et al. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy. 2013;33(8):827–837. doi:10.1002/phar.1287
Google Scholar | Crossref | Medline6. Piazza, G, Nguyen, TN, Cios, D, et al. Anticoagulation-associated adverse drug events. Am J Med. 2011;124(12):1136–1142.
Google Scholar | Crossref | Medline7. Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
Google Scholar | Crossref | Medline | ISI8. Patel, MR, Mahaffey, KW, Garg, J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
Google Scholar | Crossref | Medline | ISI9. Granger, CB, Alexander, JH, McMurray, JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
Google Scholar | Crossref | Medline | ISI10. Shoeb, M, Fang, MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013;35(3):312–319.
Google Scholar | Crossref | Medline11. Hindricks, G, Potpara, T, Dagres, N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
Google Scholar | Crossref | Medline12. January, C, Wann, L, Calkins, H, Chen, L, Cigarroa, J. 2019 AHA / ACC / HRS focused update of the 2014 guideline for management of patients with atrial fibrillation 2019 AHA / ACC / HRS focused update of the 2014 guideline for management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):14–132.
Google Scholar13. Hinojar, R, Jiménez-Natcher, JJ, Fernández-Golfín, C, Zamorano, JL. New oral anticoagulants: a practical guide for physicians. Eur Hear J Cardiovasc Pharmacother. 2015;1(2):134–145.
Google Scholar | Crossref | Medline14. Zirlik, A, Bode, C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43(3):365–379.
Google Scholar | Crossref | Medline15. PRADAXA (Dabigatran etexilate) [prescribing information]. Hertzliya Pituach, Israel: Boehringer Ingelheim Israel Ltd; 2017.
Google Scholar16. XARELTO (Rivaroxaban) [prescribing information]. Hod Hasharon, Israel: Bayer Israel Ltd; 2018.
Google Scholar17. ELIQUIS (Apixaban) [summary of product characteristics]. Herzeliya, Israel: Pfizer Pharmaceuticals Israel Ltd; 2018.
Google Scholar18. Steffel, J, Verhamme, P, Potpara, TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Hear J. 2018;39(16):1330–1393.
Google Scholar | Crossref | Medline19. Gong, IY, Kim, RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29(7 suppl):24–33.
Google Scholar | Crossref20. Lopes, RD, Hong, H, Harskamp, RE, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol. 2019;4(8):747–755. doi:10.1001/jamacardio.2019.1880
Google Scholar | Crossref | Medline21. Larock, AS, Mullier, F, Sennesael, AL, et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother. 2014;48(10):1258–1268.
Google Scholar | SAGE Journals | ISI22. Simon, J, Hawes, E, Deyo, Z, Bryant Shilliday, B. Evaluation of prescribing and patient use of target-specific oral anticoagulants in the outpatient setting. J Clin Pharm Ther. 2015;40(5):525–530.
Google Scholar | Crossref | Medline | ISI23. Pharithi, RB, Ranganathan, D, Brien, JO, et al. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke pre. Ir J Med Sci. 2019;188(1):101–108. doi:10.1007/s11845-018-1837-7.
Google Scholar | Crossref | Medline24. Moudallel, S, Steurbaut, S, Cornu, P, Dupont, A. Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. Front Pharmacol. 2018;9:1–10.
Google Scholar | Crossref | Medline25. Pattullo, CS, Barras, M, Tai, B, McKean, M, Donovan, P. New oral anticoagulants: appropriateness of prescribing in real-world setting. Intern Med J. 2016;46(7):812–818.
Google Scholar | Crossref | Medline26. Başaran, Ö, Dogan, V, Beton, O, et al. Suboptimal use of non-vitamin K antagonist oral anticoagulants: results from the RAMSES study. Medicine (Baltimore). 2016;95(35):e4672. doi:10.1097/MD.0000000000004672
Google Scholar | Crossref | Medline27. Steinberg, BA, Shrader, P, Thomas, L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68(24):2597–2604.
Google Scholar | Crossref | Medline28. Chowdhry, U, Jacques, A, Karovitch, A, Giguère, P, Nguyen, ML. Appropriateness of dabigatran and rivaroxaban prescribing for hospital inpatients. Can J Hosp Pharm. 2016;69(3):194. doi:10.4212/cjhp.v69i3.1555
Google Scholar | Medline29. Viprey, M, Jeannin, R, Piriou, V, et al. Prevalence of drug-related problems associated with direct oral anticoagulants in hospitalized patients: a multicenter, cross-sectional study. J Clin Pharm Ther. 2017;42(1):58–63. doi:10.1111/jcpt.12473
Google Scholar | Crossref | Medline30. Başaran, Ö, Başaran, NF, Cekic, EG, et al. PRescriptiOn PattERns of oral anticoagulants in nonvalvular atrial fibrillation (PROPER study). Clin Appl Thromb Hemost. 2017;23(4):384–391.
Google Scholar | SAGE Journals31. Whitworth, MM, Haase, KK, Fike, DS, Bharadwaj, RM, Young, RB, MacLaughlin, EJ. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gen Med. 2017;10:87–94.
Google Scholar | Crossref | Medline32. Gibson, CM, Smith, CB, Davis, S, Scalese, MJ. Assessment of apixaban prescribing patterns for nonvalvular atrial fibrillation in hospitalized patients. Ann Pharmacother. 2018;52(1):54–59.
Google Scholar | SAGE Journals | ISI33. Kaatz, S, Ahmad, D, Spyropoulos, AC, Schulman, S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–2126. doi:10.1111/jth.13140
Google Scholar | Crossref | Medline34. Charlson, ME, Pompei, P, Ales, KL, MacKenzie, R. A new method of classifying prognostic in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
Google Scholar | Crossref | Medline35. Levey, AS, Bosch, JP, Lewis, JB, Greene, T, Rogers, N, Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–470.
Google Scholar | Crossref | Medline | ISI36. Lip, GYH, Nieuwlaat, R, Pisters, R, Lane, DA, Crijns, HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584
Google Scholar | Crossref | Medline | ISI37. Pisters, R, Lane, DA, Nieuwlaat, R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010;138(5):1093–1100. doi:10.1378/chest.10-0134
Google Scholar | Crossref | Medline | ISI38. Pharmaceutical Care Network Europe Foundation . PCNE Classification scheme for Drug-Related Problems V8.03. Published 2019. Accessed May 19, 2021. https://www.pcne.org/upload/files/318_PCNE_classification_V8-03.pdf
Google Scholar39. Collet, J-P, Thiele, H, Barbato, E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575
Google Scholar | Crossref | Medline40. Valgimigli, M, Bueno, H, Byrne, RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213–254. doi:10.1093/eurheartj/ehx419
Google Scholar | Crossref | Medline41. Angel, Y, Zeltser, D, Berliner, S, et al. Hospitalization as an opportunity to correct errors in anticoagulant treatment in patients with atrial fibrillation. Br J Clin Pharmacol. 2019;85(12):2838–2847. doi:10.1111/bcp.14116
Google Scholar | Crossref | Medline42. Perlman, A, Horwitz, E, Hirsh-Raccah, B, et al. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Isr J Health Policy Res. 2019;8(1):1–9. doi:10.1186/s13584-019-0285-9
Google Scholar | Crossref | Medline43. Sen, S, Dahlberg, KW. Physician’s fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci. 2014;348(6):513–521.
Google Scholar | Crossref | Medline44. Santos, J, António, N, Rocha, M, Fortuna, A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol. 2020;86(3):533–547. doi:10.1111/bcp.14127
Google Scholar | Crossref | Medline45. Sorajja, D, Shen, W, Noseworthy, PA. Long-term clinical outcomes of underdosed direct oral anticoagulants in patients with atrial fibrillation and atrial flutter [published online January 12, 2021]. Am J Med. 2021. doi:10.1016/j.amjmed.2020.12.022
Google Scholar | Medline46. Wakamatsu, Y, Nagashima, K, Watanabe, R, et al. Clinical outcomes of off-label underdosing of direct oral anticoagulants after ablation for atrial fibrillation: subanalysis of the AF frontier ablation registry. Int Heart J. 2020;61(6):1165–1173. doi:10.1536/ihj.20-335
Google Scholar | Crossref | Medline47. Yu, HT, Yang, PS, Jang, E, et al. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2020;9(12):e014177. doi:10.1161/JAHA.119.014177
Google Scholar | Crossref | Medline48. Dans, AL, Connolly, SJ, Wallentin, L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013;127(5):634–640. doi:10.1161/CIRCULATIONAHA.112.115386
Google Scholar | Crossref | Medline | ISI49. Lamberts, M, Staerk, L, Olesen, JB, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. J Am Hear Assoc. 2017;6(2):e004517. doi:10.1161/JAHA.116.004517
Google Scholar | Crossref |